BSE · 530163
Kerala Ayurveda Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹23 Cr with net profit ₹-8 Cr — a -34.04% net margin, versus -32.28% the period before.
Shareholding
As of 2026-10-31
- Promoter38.7%
- Public61.12%
- FII0.15%
- DII0.03%
10,580 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.15× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #25 of 51 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,80,675 Cr | 83.22 | 9.81 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹52,297 Cr | 45.64 | 5.05 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹41,333 Cr | 32.73 | 8.51 | 25.99% | 20.31% |
| Rubicon Research Limited | ₹27,468 Cr | 95.31 | 19.38 | 22.94% | 15.47% |
| Shilpa Medicare Ltd. | ₹18,431 Cr | 64.81 | 6.68 | 12.05% | 18.05% |
| Caplin Point Laboratories Ltd. | ₹18,110 Cr | 27.22 | 5.37 | 17.88% | 29.09% |
| Eris Lifesciences Limited | ₹17,122 Cr | 22.87 | 4.12 | 17.07% | 21.36% |
| Marksans Pharma Limited | ₹13,764 Cr | 24.59 | 4.13 | 16.8% | 16.51% |
| Bliss GVS Pharma Ltd. | ₹6,535 Cr | 40.17 | 4.97 | 12.49% | 15.01% |
| Senores Pharmaceuticals Limited | ₹5,347 Cr | 40.06 | 5.32 | 13.31% | 18.57% |
| Kerala Ayurveda Ltd.(this company) | ₹196 Cr | — | 8.19 | -148.86% | -19.55% |
AI analysis
AI-generated · google/gemini-2.5-flashKerala Ayurveda Ltd. has a market capitalization of Rs 214 Cr. The company reported a revenue of Rs 122.15 Cr and a profit margin of -12.63%. Its debt-to-equity ratio stands at 5.21. The promoter holding as of June 30, 2026, was 35.606%, with 20.35% of promoter shares pledged.
Positives
- +No specific strengths can be identified from the provided financial data.
Negatives
- −The company reported a negative profit margin of -12.63%.
- −Return on equity (ROE) is significantly negative at -148.86%.
- −Return on capital employed (ROCE) is negative at -9.231%.
- −The debt-to-equity ratio is high at 5.21.
- −20.35% of the promoter's shareholding is pledged.
- −EPS is 0, indicating no earnings per share.
Financial Performance
For the period ending March 2026, the company reported an annual revenue of Rs 24.57 Cr with a net profit of -Rs 7.93 Cr. In the preceding quarter ending December 2025, revenue was Rs 32.96 Cr, and net profit was -Rs 4.45 Cr. The latest reported quarterly revenue for March 2026 was Rs 34.74 Cr, with a net profit of -Rs 7.76 Cr.
Profitability & Returns
Kerala Ayurveda Ltd. has an EPS of 0 and a negative profit margin of -12.63%. The return on equity (ROE) is -148.86%, and the return on capital employed (ROCE) is -9.231%, indicating that the company is not generating profits efficiently from its equity or capital.
Balance Sheet
The company has a book value per share of Rs 8.79. The debt-to-equity ratio is high at 5.21, suggesting a significant reliance on debt financing. No specific debt figures are available, but the ratio indicates substantial leverage.
Ownership & Pledges
The public shareholding stands at 64.1911%. A total of 20.35% of the promoter shareholding is pledged, specifically 941,667 shares held by Katra Holdings Ltd.
Quarterly Performance
In the quarter ending March 2026, the company recorded revenue of Rs 34.74 Cr and a net profit of -Rs 7.76 Cr. This follows a revenue of Rs 32.96 Cr and a net profit of -Rs 4.45 Cr in the December 2025 quarter. The September 2025 quarter saw a revenue of Rs 34.84 Cr and net profit of -Rs 6.34 Cr.
Data as of — price: 2026-11-07 · financials: Jun 26 · shareholding: Oct 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.